Study on EGFR tyrosine kinase inhibitor drug Osimertinib resistance in EGFR mutant NSCLC for analysis of immunohistochemistory of tumor tissues.

Study on EGFR tyrosine kinase inhibitor drug Osimertinib resistance in EGFR mutant NSCLC for analysis of immunohistochemistory of tumor tissues. - Study on Osimertinib resistance mechanism

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000037294

Enrollment

Registered

2019-07-06

Start date

2019-07-06

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Pathologically diagnosed with non-small cell lung cancer 2)Harboring EGFR mutation 3)Prior treatment history with Osimertinib 4)Adequate histological sample after resistance to Osimertinib 5)Provided informed consent

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Novel resistant mechanism to Osimertinib	—

Countries

Japan,North America

Contacts

Public ContactKeita Miura

Juntendo University Respiratory Medicine

k-miura@juntendo.ac.jp03-5802-1063

Outcome results